Welcome to our dedicated page for Cyclo Therapeutics news (Ticker: CYTH), a resource for investors and traders seeking the latest updates and insights on Cyclo Therapeutics stock.
Cyclo Therapeutics Inc. (CYTH) is a clinical-stage biotechnology company advancing cyclodextrin-based therapies for rare neurodegenerative diseases, including Niemann-Pick Type C. This page provides investors and researchers with timely updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Access the latest press releases, financial reports, and scientific developments related to Trappsol Cyclo and other pipeline programs. Our curated news collection ensures transparent tracking of corporate announcements, partnership agreements, and research advancements in cyclodextrin therapeutics.
Key updates include clinical trial data, FDA communications, intellectual property filings, and industry conference presentations. Bookmark this page for centralized access to verified information supporting informed analysis of Cyclo Therapeutics’ progress in addressing unmet medical needs.
Cyclo Therapeutics (NASDAQ: CYTH) reported significant advancements in its clinical programs, particularly for Trappsol® Cyclo™ targeting Niemann-Pick Disease Type C1 (NPC1) and Alzheimer’s Disease. The ongoing Phase 3 study, TransportNPC™, aims to provide the first FDA-approved therapy for NPC. In 2021, the company faced a net loss of approximately $14.3 million, with R&D expenses increasing by 50% to $9.2 million due to heightened clinical activity. As of year-end, Cyclo held $16.6 million in cash and anticipates further R&D cost increases in 2022 as it progresses its clinical studies.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) has announced a presentation by CEO N. Scott Fine at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 PM ET. The event includes a live video webcast and opportunities for virtual one-on-one meetings with investors.
The company is focused on developing treatments for rare diseases, particularly Niemann-Pick Disease Type C, with its Trappsol® Cyclo™ drug currently undergoing multiple clinical trials.
Cyclo Therapeutics (NASDAQ: CYTH) presented its ongoing pivotal Phase 3 study, TransportNPC™, at the 18th Annual WORLD Symposium 2022. The trial focuses on the efficacy of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1, with results expected in 96 weeks. Designed in collaboration with regulatory bodies and experts, the study aims to enroll at least 93 patients across 23 centers in 9 countries. Cyclo Therapeutics has received various designations for Trappsol® Cyclo™, highlighting its commitment to addressing unmet medical needs in this patient population.
Cyclo Therapeutics (NASDAQ: CYTH) announced the formation of a Global Steering Committee to oversee its pivotal Phase 3 study, TransportNPC™, for treating Niemann-Pick Disease Type C (NPC). This multicenter trial aims to evaluate the safety and efficacy of Trappsol® Cyclo™. Preliminary data suggests potential for disease stabilization with home-based infusions. The study will enroll at least 93 pediatric and adult patients across 9 countries, featuring a randomized, placebo-controlled design with a 96-week duration and an interim analysis at 48 weeks.
Cyclo Therapeutics (Nasdaq: CYTH) announced a live video webcast presentation on January 27, 2022, at 10:00 AM ET during the Virtual Investor 2022 Top Picks Conference. CEO N. Scott Fine will present followed by a moderated discussion and Q&A session, allowing live and pre-submitted questions from investors. A webcast replay will be available for one year after the event. Cyclo Therapeutics is focused on developing treatments for rare diseases, including Niemann-Pick Disease Type C, and is preparing for trials involving Alzheimer's Disease.
Cyclo Therapeutics has appointed Dr. Caroline Hastings as Global Principal Investigator for the pivotal Phase 3 study, TransportNPC™, aimed at treating Niemann-Pick Disease Type C1. The study, currently enrolling patients, evaluates the efficacy of Trappsol® Cyclo™ over 96 weeks across 23 centers in 9 countries. Preliminary data show promising results, suggesting disease stabilization and safety over two years. The company also received positive feedback from the EMA regarding its pediatric investigation plan.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that the FDA has approved its IND application to proceed with a Phase 2 study of Trappsol® Cyclo™ for early Alzheimer’s disease. The company expressed satisfaction with the FDA's feedback and aims to address the critical need for effective treatments. Trappsol® Cyclo™ has demonstrated potential in managing cholesterol transport, which is linked to Alzheimer’s pathology. Cyclo Therapeutics is also advancing its treatment for Niemann-Pick disease Type C1, reinforcing its commitment to neurodegenerative disease therapies.
Cyclo Therapeutics has priced its public offering of 1,950,000 shares at $6.00 per share, expected to raise $11.7 million in gross proceeds. The underwriter, Maxim Group LLC, has a 45-day option to purchase an additional 292,500 shares. This offering is made under an effective shelf registration statement with the SEC. The funds will support the company's clinical developments, including trials for Niemann-Pick Disease Type C and potential Alzheimer's applications.
Cyclo Therapeutics has initiated an underwritten public offering of its common stock, with details subject to market conditions. The offering is conducted by Maxim Group LLC as the sole book-running manager and will follow an effective shelf registration statement filed with the SEC. The company aims to secure funding to support its clinical trials for Trappsol® Cyclo™, which is currently involved in four trials for Niemann-Pick Disease Type C and is exploring further applications in Alzheimer’s Disease.
Cyclo Therapeutics (NASDAQ: CYTH) has submitted an initial investigational new drug (IND) application to the FDA for Trappsol® Cyclo™, targeting early Alzheimer’s Disease. The Phase 2 study design is based on clinical data from Niemann-Pick Disease Type C and 18 months' experience with a late-onset Alzheimer’s patient. The drug aims to address cholesterol accumulation and oxidative stress, conditions shared in both diseases. The company highlights significant unmet needs in Alzheimer’s treatment, positioning Trappsol® Cyclo™ as a potential solution.
FAQ
What is the current stock price of Cyclo Therapeutics (CYTH)?
What is the market cap of Cyclo Therapeutics (CYTH)?
